MAZE (STOCKS)
Maze Therapeutics, Inc. Common Stock
$27.730000
+0.200000 (+0.73%)
Prev close: $27.530000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jason V. Coloma
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,534.72M
- Employees
- 125
- P/E (TTM)
- -10.87
- P/B (TTM)
- 3.37
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.45 | $-0.56 | +0.1065 | +19.14% |
|
Dec 2025 (Q4)
|
$-0.65 | $-0.73 | +0.0779 | +10.70% |
|
Sep 2025 (Q3)
|
$-0.66 | $-0.72 | +0.0627 | +8.68% |
|
Jun 2025 (Q2)
|
$-0.77 | $-0.87 | +0.1031 | +11.81% |
Financial Statements
| Revenues | $20.00M |
| Operating Expenses | $165.61M |
| Research and Development | $121.85M |
| Other Operating Expenses | $43.76M |
| Operating Income/Loss | -$145.61M |
| Income/Loss From Continuing Operations After Tax | -$133.59M |
| Income/Loss From Continuing Operations Before Tax | -$133.59M |
| Net Income/Loss | -$133.59M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$133.59M |
| Net Income/Loss Available To Common Stockholders, Basic | -$133.59M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.48 |
| Diluted Earnings Per Share | -$2.48 |
| Basic Average Shares | 105,751,627 |
| Diluted Average Shares | 105,751,627 |
| Assets | $531.63M |
| Current Assets | $420.42M |
| Noncurrent Assets | $111.20M |
| Fixed Assets | $4.39M |
| Other Non-current Assets | $106.81M |
| Liabilities | $78.50M |
| Current Liabilities | $22.96M |
| Accounts Payable | $2.21M |
| Wages | $6.93M |
| Other Current Liabilities | $13.82M |
| Noncurrent Liabilities | $55.54M |
| Long-term Debt | $38.96M |
| Other Non-current Liabilities | $16.58M |
| Equity | $453.12M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $453.12M |
| Liabilities And Equity | $531.63M |
| Net Cash Flow From Operating Activities | -$106.54M |
| Net Cash Flow From Operating Activities, Continuing | -$106.54M |
| Net Cash Flow From Investing Activities | -$292.50M |
| Net Cash Flow From Investing Activities, Continuing | -$292.50M |
| Net Cash Flow From Financing Activities | $337.14M |
| Net Cash Flow From Financing Activities, Continuing | $337.14M |
| Net Cash Flow | -$61.90M |
| Net Cash Flow, Continuing | -$61.90M |
| Comprehensive Income/Loss | -$133.78M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$134.03M |
| Other Comprehensive Income/Loss | -$75.00M |